BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36891725)

  • 1. [The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].
    Fan ZH; Ren F
    Zhonghua Gan Zang Bing Za Zhi; 2022 Dec; 30(12):1382-1386. PubMed ID: 36891725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA and Hepatocellular Carcinoma.
    Yang JD; Liu MC; Kisiel JB
    Semin Liver Dis; 2019 Nov; 39(4):452-462. PubMed ID: 31226727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
    Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
    Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.
    Xu RH; Wei W; Krawczyk M; Wang W; Luo H; Flagg K; Yi S; Shi W; Quan Q; Li K; Zheng L; Zhang H; Caughey BA; Zhao Q; Hou J; Zhang R; Xu Y; Cai H; Li G; Hou R; Zhong Z; Lin D; Fu X; Zhu J; Duan Y; Yu M; Ying B; Zhang W; Wang J; Zhang E; Zhang C; Li O; Guo R; Carter H; Zhu JK; Hao X; Zhang K
    Nat Mater; 2017 Nov; 16(11):1155-1161. PubMed ID: 29035356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylated circulating tumor DNA in hepatocellular carcinoma: A comprehensive analysis of biomarker potential and clinical implications.
    Zhu Q; Xie J; Mei W; Zeng C
    Cancer Treat Rev; 2024 Jul; 128():102763. PubMed ID: 38763055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
    Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
    J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
    Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
    Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
    Weng J; Atyah M; Zhou C; Ren N
    Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
    Dhayat SA; Yang Z
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
    Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
    Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
    Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
    Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma.
    Ding Y; Yao J; Wen M; Liu X; Huang J; Zhang M; Zhang Y; Lv Y; Xie Z; Zuo J
    PeerJ; 2022; 10():e13473. PubMed ID: 35602894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
    Moldogazieva NT; Zavadskiy SP; Terentiev AA
    Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Pedersen MH; Weber B; Aagaard NK; Villadsen GE; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    Scand J Gastroenterol; 2020 Dec; 55(12):1433-1440. PubMed ID: 33103505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
    Lyu X; Tsui YM; Ho DW; Ng IO
    Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
    Lin J; Zhao S; Wang D; Song Y; Che Y; Yang X; Mao J; Xie F; Long J; Bai Y; Yang X; Zhang L; Bian J; Lu X; Sang X; Pan J; Wang K; Zhao H
    Front Immunol; 2021; 12():673248. PubMed ID: 34211467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
    Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R
    Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
    von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
    Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.